Entries by Thomas Gabrielczyk

Solar Foods starts Factory01

Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.

Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio

Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).

TME Pharma gets FDA Fast Track for Glioblastoma

TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.

Chemspec Europe 2024

Connect with the world of fine and speciality chemicals: taking place from 19-20 June 2024 at the Messe Düsseldorf exhibition centre in Germany, Chemspec Europe is the key marketplace to showcase the full array of fine and speciality chemicals, bespoke ­solutions, services, and equipment.  

Forbion participates in US financing rounds

Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.